By Drug Target Review2025-08-22T14:30:45
The 2025 chikungunya outbreak has surged from the Indian Ocean to Europe, prompting an urgent global research response. With no antivirals and limited vaccine access, laboratories and biotech firms are under pressure to deliver solutions fast.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2026-03-27T13:06:00Z
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2025-07-30T08:00:00
Sponsored by Wuxi Biologics
2023-01-06T10:25:33
Sponsored by Leica Microsystems
2023-03-03T14:06:14
Sponsored by Bio-Techne
2023-03-08T16:29:20
Sponsored by Bio-Techne
Site powered by Webvision Cloud